ADC Therapeutics SA Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss
ADC Therapeutics SA (ADCT) reported Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss of $39.00 thousand for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss · last filed 2023-11-07
- ADC Therapeutics SA gains losses on exchange differences on translation recognised in profit or loss for the quarter ending 2023-09-30 was $39.00K.
- ADC Therapeutics SA gains losses on exchange differences on translation recognised in profit or loss for the quarter ending 2023-06-30 was $18.00K, a 91.93% decline year-over-year.
- ADC Therapeutics SA gains losses on exchange differences on translation recognised in profit or loss for the quarter ending 2023-03-31 was -$52.00K, a 164.20% decline year-over-year.
- ADC Therapeutics SA gains losses on exchange differences on translation recognised in profit or loss for the quarter ending 2022-12-31 was -$358.00K.
| Period end | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 3 month | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 6 month | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 9 month | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 12 month |
|---|---|---|---|---|
| 2023-09-30 | $39.00K 6-K · filed 2023-11-07 | $57.00K derived: sum of 2 quarters · filed 2023-11-07 | $5.00K 6-K · filed 2023-11-07 | -$353.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $18.00K 6-K · filed 2023-08-08 | -$34.00K 6-K · filed 2023-08-08 | -$392.00K derived: sum of 3 quarters · filed 2023-08-08 | -$448.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | -$52.00K 6-K · filed 2023-05-09 | -$410.00K derived: sum of 2 quarters · filed 2023-05-09 | -$466.00K derived: sum of 3 quarters · filed 2023-11-07 | -$243.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | -$358.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$414.00K derived: sum of 2 quarters · filed 2023-11-07 | -$191.00K derived: sum of 3 quarters · filed 2023-11-07 | -$110.00K 20-F · filed 2023-03-15 |
| 2022-09-30 | -$56.00K 6-K · filed 2023-11-07 | $167.00K derived: sum of 2 quarters · filed 2023-11-07 | $248.00K 6-K · filed 2023-11-07 | $153.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $223.00K 6-K · filed 2023-08-08 | $304.00K 6-K · filed 2023-08-08 | $209.00K derived: sum of 3 quarters · filed 2023-08-08 | $202.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $81.00K 6-K · filed 2023-05-09 | -$14.00K derived: sum of 2 quarters · filed 2023-05-09 | -$21.00K derived: sum of 3 quarters · filed 2023-05-09 | -$263.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$95.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$102.00K derived: sum of 2 quarters · filed 2023-03-15 | -$344.00K derived: sum of 3 quarters · filed 2023-03-15 | $50.00K 20-F · filed 2023-03-15 |
| 2021-09-30 | -$7.00K 6-K · filed 2022-11-08 | -$249.00K derived: sum of 2 quarters · filed 2022-11-08 | $145.00K 6-K · filed 2022-11-08 | -$221.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$242.00K 6-K · filed 2022-08-09 | $152.00K 6-K · filed 2022-08-09 | -$214.00K derived: sum of 3 quarters · filed 2023-03-15 | -$353.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $394.00K 6-K · filed 2022-05-09 | $28.00K derived: sum of 2 quarters · filed 2023-03-15 | -$111.00K derived: sum of 3 quarters · filed 2023-03-15 | -$211.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$366.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$505.00K derived: sum of 2 quarters · filed 2023-03-15 | -$605.00K derived: sum of 3 quarters · filed 2023-03-15 | -$576.00K 20-F · filed 2023-03-15 |
| 2020-09-30 | -$139.00K 6-K · filed 2021-11-02 | -$239.00K derived: sum of 2 quarters · filed 2021-11-02 | -$210.00K 6-K · filed 2021-11-02 | |
| 2020-06-30 | -$100.00K 6-K · filed 2021-08-03 | -$71.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $29.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | -$255.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $213.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |